Cargando…
Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials
Purpose: Reliable risk estimates of recurrence are necessary to establish optimal postoperative surveillance strategies. The purpose of the present study was to clarify changes in the hazard rate (HR) for tumor recurrence over time in Japanese patients with colon cancer. Methods: Data for 3984 patie...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Ivyspring International Publisher
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706008/ https://www.ncbi.nlm.nih.gov/pubmed/29187881 http://dx.doi.org/10.7150/jca.21365 |
_version_ | 1783282140392194048 |
---|---|
author | Maeda, Hiromichi Kashiwabara, Kosuke Aoyama, Toru Oba, Koji Honda, Michitaka Mayanagi, Shuhei Kanda, Mitsuro Hamada, Chikuma Sadahiro, Sotaro Sakamoto, Junichi Saji, Shigetoyo Yoshikawa, Takaki |
author_facet | Maeda, Hiromichi Kashiwabara, Kosuke Aoyama, Toru Oba, Koji Honda, Michitaka Mayanagi, Shuhei Kanda, Mitsuro Hamada, Chikuma Sadahiro, Sotaro Sakamoto, Junichi Saji, Shigetoyo Yoshikawa, Takaki |
author_sort | Maeda, Hiromichi |
collection | PubMed |
description | Purpose: Reliable risk estimates of recurrence are necessary to establish optimal postoperative surveillance strategies. The purpose of the present study was to clarify changes in the hazard rate (HR) for tumor recurrence over time in Japanese patients with colon cancer. Methods: Data for 3984 patients from three clinical trials evaluating the benefit of adjuvant chemotherapy for colon cancer were analyzed. Estimated HRs were plotted over time for the entire cohort, as well as for node-positive and node-negative patients separately. The changes in risk were further analyzed according to eight clinical variables, and factors predictive of early (<3 years) and late (>3 years) recurrence were explored using Cox's regression analysis. Results: In node-positive patients, there was a prominent HR peak 0.6 years after surgery, whereas HR remained at consistently low levels in node-negative patients. In node-positive patients, HR decreased steadily until 3 years, after which the decline in HR plateaued. Those with T4 tumors had a prominent HR peak around 1 year, including node-negative patients. The HR for T1/T2 Stage III colon cancers showed a similar pattern as that for T1-T3 node-negative colon cancers. Cox regression analysis revealed that a lack of adjuvant chemotherapy, positive node status, T3/T4 factors, and male gender predict early recurrence, whereas patients with lymph node metastasis, T4 tumors, and a lesser extent of lymph node removal have a higher risk of recurrence 3-4 years after surgery (P<0.05). Conclusion: The present study supports the concept of intensive surveillance during the first 3 years after curative resection. However, a reduction in surveillance intensity may be acceptable for patients with T3 Stage II and T1/T2 Stage III colon cancer. |
format | Online Article Text |
id | pubmed-5706008 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | Ivyspring International Publisher |
record_format | MEDLINE/PubMed |
spelling | pubmed-57060082017-11-29 Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials Maeda, Hiromichi Kashiwabara, Kosuke Aoyama, Toru Oba, Koji Honda, Michitaka Mayanagi, Shuhei Kanda, Mitsuro Hamada, Chikuma Sadahiro, Sotaro Sakamoto, Junichi Saji, Shigetoyo Yoshikawa, Takaki J Cancer Research Paper Purpose: Reliable risk estimates of recurrence are necessary to establish optimal postoperative surveillance strategies. The purpose of the present study was to clarify changes in the hazard rate (HR) for tumor recurrence over time in Japanese patients with colon cancer. Methods: Data for 3984 patients from three clinical trials evaluating the benefit of adjuvant chemotherapy for colon cancer were analyzed. Estimated HRs were plotted over time for the entire cohort, as well as for node-positive and node-negative patients separately. The changes in risk were further analyzed according to eight clinical variables, and factors predictive of early (<3 years) and late (>3 years) recurrence were explored using Cox's regression analysis. Results: In node-positive patients, there was a prominent HR peak 0.6 years after surgery, whereas HR remained at consistently low levels in node-negative patients. In node-positive patients, HR decreased steadily until 3 years, after which the decline in HR plateaued. Those with T4 tumors had a prominent HR peak around 1 year, including node-negative patients. The HR for T1/T2 Stage III colon cancers showed a similar pattern as that for T1-T3 node-negative colon cancers. Cox regression analysis revealed that a lack of adjuvant chemotherapy, positive node status, T3/T4 factors, and male gender predict early recurrence, whereas patients with lymph node metastasis, T4 tumors, and a lesser extent of lymph node removal have a higher risk of recurrence 3-4 years after surgery (P<0.05). Conclusion: The present study supports the concept of intensive surveillance during the first 3 years after curative resection. However, a reduction in surveillance intensity may be acceptable for patients with T3 Stage II and T1/T2 Stage III colon cancer. Ivyspring International Publisher 2017-10-23 /pmc/articles/PMC5706008/ /pubmed/29187881 http://dx.doi.org/10.7150/jca.21365 Text en © Ivyspring International Publisher This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions. |
spellingShingle | Research Paper Maeda, Hiromichi Kashiwabara, Kosuke Aoyama, Toru Oba, Koji Honda, Michitaka Mayanagi, Shuhei Kanda, Mitsuro Hamada, Chikuma Sadahiro, Sotaro Sakamoto, Junichi Saji, Shigetoyo Yoshikawa, Takaki Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title_full | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title_fullStr | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title_full_unstemmed | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title_short | Hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three Japanese Foundation for Multidisciplinary Treatment of Cancer (JFMC) clinical trials |
title_sort | hazard rate of tumor recurrence over time in patients with colon cancer: implications for postoperative surveillance from three japanese foundation for multidisciplinary treatment of cancer (jfmc) clinical trials |
topic | Research Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706008/ https://www.ncbi.nlm.nih.gov/pubmed/29187881 http://dx.doi.org/10.7150/jca.21365 |
work_keys_str_mv | AT maedahiromichi hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT kashiwabarakosuke hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT aoyamatoru hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT obakoji hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT hondamichitaka hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT mayanagishuhei hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT kandamitsuro hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT hamadachikuma hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT sadahirosotaro hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT sakamotojunichi hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT sajishigetoyo hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials AT yoshikawatakaki hazardrateoftumorrecurrenceovertimeinpatientswithcoloncancerimplicationsforpostoperativesurveillancefromthreejapanesefoundationformultidisciplinarytreatmentofcancerjfmcclinicaltrials |